Armistice Capital, LLC, Director, 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 226,000 shares at $0.69 ($152K) on 2022-03-11, disclosed to the SEC on 2022-03-14.
Open-market purchase of $152k AVTX by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.70 | 26,000 | $18K | 12.0% |
| 2 | $0.69 | 100,000 | $69K | 45.3% |
| 3 | $0.65 | 100,000 | $65K | 42.7% |
| Total | $0.67 avg | 226,000 | $152K | 100% |
| Filing → |
| CERC | BUY | 2021-08-06 | $409K | — | Filing → |
| EYEG | SELL | 2021-08-03 | $830K | — | Filing → |
| CERC | BUY | 2021-05-18 | $392K | — | Filing → |